In a retrospective study the expression of the c-erbB-2 oncogene was determined immunohistochemically in 276 breast cancer samples from 253 patients with the antibody 21N. The follow-up period was between 7 and 12 years. This study showed a trend for an inverse relationship between c-erbB-2 positive tumours and estrogen receptors (ER). A correlation was assessed between c-erbB-2 positive tumours and histological grade, liver metastases as first site of metastases, disease free survival time (DFS) in the second and third year after diagnosis and overall survival time (OST) in the third and fourth year after diagnosis. A trend was seen between c-erbB-2 positive tumours and tumour size. No correlation was found between c-erbB-2 positive tumours and age at diagnosis. The method of operation and lymph node involvement. From this study we conclude that there is a significant difference in prognosis the first years after diagnosis, but this difference seems to vanish in a longer follow-up period of 12 years. This provides us with an explanation for the discrepancies in literature concerning c-erbB-2 expression and prognosis in breast cancer. Some investigators did not show differences in prognosis between positive and negative cases after a long follow-up period whereas investigations with a short term follow-up period up to 2-3 years have indeed established a more aggressive behaviour of c-erbB-2 overexpressionary tumours.
The c-erbB-2 or HER-2/neu oncogene encodes a transmembraneous glycoprotein with tyrosine kinase activity. The gene was first described in rat neuroglioblastoma induced by treatment with a carcinogen (Schechter et al., 1984) . C-erbB-2 or neu has important sequence homology with the epidermal growth factor receptor. (Schechter et al., 1984; Bargmann et al., 1986) . Amplification and overexpression were found especially in breast cancer (Yakota et al., 1986) and gastric carcinomas (Falck & Gullick, 1989) .
Increased copy numbers in breast carcinomas were related to bad prognosis by some authors Slamon et al., 1987; Varley et al., 1987; Slamon et al., 1989) . These results were refuted by others (Ali et al., 1988; Zhou et al., 1989) . Gene amplification of c-erbB-2 correlated with lymphnode involvement (Slamon et al., 1987; Zhou et al., 1987; Slamon et al., 1989; Guerin et al., 1989; Tavassoli et al., 1989) , histological grade (Berger et al., 1988; Tavassoli et al., 1989; Tsuda et al., 1989 , Paik et al., 1990 , negative ERcontent Guerin et al., 1989; Zeillinger et al., 1989; Heintz et al., 1990) , early recurrence (Zhou et al., 1987; Cline et al., 1987; Varley et al., 1987) , short overall survival time Slamon et al., 1987; Varley et al., 1987; Slamon et al., 1989; Paik et al., 1990) and increased mitotic activity (Heintz et al., 1990; Ramachandra et al., 1990) . All of these factors are considered to be bad prognostic indicators. According to other authors there was no correlation with tumour size (Gutman et al., 1989; Seshadri et al., 1989) and age at diagnosis (Zhou et al., 1987; Seshadri et al., 1989) .
Studies were also carried out on the protein of c-erbB-2 by the immunoperoxidase method on primary cancers and metastases. Correlations were found between membrane staining tumours and patho-histological findings such as tumour size (van de Vijver et al., 1988) , negative ER-content (De Potter et al., 1989a; Thor et al., 1989; Wright et al., 1989a; Kommoss et al., 1990; De Potter et al., 1990) , lymph node involvement (Berger et al., 1988; Thor et al., 1989) , histological grade (berger et al., 1988; Barnes et al., 1988; Wright et al., 1989a) and survival time (Thor et al., 1989; Wright et al., 1989a) .
Furthermore a trend towards worse prognosis was found by others (Barnes et al., 1988; Thor et al., 1989; Walker et al., 1989; Paik et al., 1990; De Potter et al., 1990 (5) The peroxidase reaction was developed using 3-3 diaminobenzidine (Sigma, St Louis -USA) with 0.01% hydrogen peroxide for 10 min followed by washing in tap water. The nuclei were counterstained with haematoxylin. All sections were dehydrated and mounted. Control specimens were prepared by omitting the primary antibody. One slide identified as being positive for c-erbB-2 was taken as positive control.
Antibody 21N as a polyclonal antibody was raised against a synthetic peptide derived from the c-erbB-2 oncogene product containing the amino acid residues 1243-1255 of the c-terminus of the protein of c-erbB-2 . (De Potter et al., 1989b) .
Statistical analysis Clinical and pathohistological factors in relation to c-erbB-2 over-expression were assessed by Fisher's exact test (Hartung, 1985) . Age at diagnosis was calculated with the Wilcoxon Rank Sum test (Hartung, 1985) .
In a multivariate analysis, using an accelerated life model (Cox & Oakes, 1984) , the relation between DFS and OST and the following prognostic factors as: C-erbB-2 overexpression, histology, lymph node status, ER, method of operation, age at diagnosis and tumour size were calculated.
The actuarial curves for DFS and OST were calculated with the Kaplan-Meier technique. The tumour size was the strongest prognostic factor in the accelerated life model. Adjusting for tumour size the probability of recurrence at fixed time periods after 6, 12, 18, . . . 36 months, respectively the probability of survival at fixed time periods after 6, 12, 18, . . . 36 months was assessed under consideration of the c-erbB-2 over-expression with the Cockran-Mantel-Haenzel test (Agresti, 1990) . Neglecting all other clinical and pathohistological factors DFS and OST were tested for the c-erbB-2 over-expression with the Log Rank and Wilcoxon test. All P-values are two sided.
Results
Tumours were only scored as positive if the membrane was stained (Figure 1) . A different cytoplasmic staining pattern was observed in some normal cells and some tumour cells, but was not considered specific for the c-erbB-2 protein. Each tumour was assessed according to the following criteria:
(1) Concerning the tumour size a trend was found between c-erbB-2 tumours and a tumour size larger than 5 cm (P = 0.055) ( Table II) . A correlation was seen between the tumours which expressed the protein of c-erbB-2 and site of first metastasis. The liver was the only tissue to have a correlation with c-erbB-2 positive tumours (P<0.05) (Table   III) . No correlation was found between the over-expression of the c-erbB-2 oncogen and age at diagnosis (P = 0.66), method of operation (P = 0.084) and axillary lymph-nodes (P = 0.18) ( Table II) . There was some difference in the membrane staining between primary tumours and their lymph node metastases. In 3/7 (42.9%) of the lymph node metastases the tumour cells showed a less marked membrane staining. The number of positive cells was also lower than in the primary tumour.
There was a significant correlation between over-expression Figure 1 Immunohistochemical staining with 21N. Invasive duct-cell carcinoma stained for the c-erbB-2 oncogene product with 21N. All tumour cells show membrane staining. (Figures 2 and 3 show the actuarial curves for DFS and OST).
Discussion
In this retrospective study the expression of the c-erbB-2 protein was determined immunohistochemically in breast cancer patients in relation to its clinical and pathohistological features. Membrane staining with antibodies against the cerbB-2 protein is known to be related to DNA amplification (Venter et al., 1987; Gusterson et al., 1988; Walker et al., 1989) and is considered to be the only expression of the c-erbB-2 oncogene, as cytoplasmic staining was shown not to be related to c-erbB-2 expression (De Potter et al., 1989b) .
We found positive membrane-staining in 15.1% of primary breast cancers. A trend for an inverse correlation was found between c-erbB-2 positive tumours and the ER status. This result confirms the studies done by De Potter et al., 1989a; Thor et al., 1989; Wright et al., 1989a; Kommuss et al., 1990; De Potter et al., 1990; O'Reilly et al., 1991. It has been demonstrated that c-erbB-2 expression is under hormonal regulation (Dati et al., 1990 ). c-erbB-2 expression is not present in breast tissue in virgin mice and in the first 2 weeks of pregnancy when oestrogen and progesterone levels are high and maximum proliferation activity is seen. Protein expression of c-erbB-2 increases at the end of pregnancy and at the beginning of the lactation period in mice, when proliferation declines and differentiation begins. Oestrogens are a controlling factor of the protein expression of c-erbB-2. Under the influence of oestrogens, c-erbB-2 expression is inhibited. This fact agrees with our findings that c-erbB-2 expression is found more frequently in ER-negative tumours. The ER negative tumours are known to behave more aggressively and to metastasise faster than ER positive tumours (Oster, 1986) . ER negative tumours, which are c-erbB-2 positive, have the tendency to respond less on hormonal therapy (Wright et al., 1989b) .
The OST in c-erbB-2 negative patients after recurrence is longer, because most of these tumours are ER positive and respond much better to hormonal treatment. Metastases of ER positive tumours are found most of the time in bone, lung, pleura and are not as aggressive as metastases in liver or brain, which are often seen in ER negative and c-erbB-2 positive patients. This fact agrees with our finding, six out of eight patients who were c-erbB-2 positive and had liver metastases died within the first 2 years after diagnosis and did not respond to any hormonal treatment.
The responsiveness of c-erbB-2 positive tumours on chemo- OST (months) Figure 3 OST in c-erbB-2 positive and negative patients at 6 month intervals. therapy is debated (Gullick et al., 1991) . The question is raised whether these tumours are resistant on chemotherapy (O'Reilly et al., 1991) , what requires further studies to investigate this hypothesis. Furthermore a trend was seen between membrane staining tumours and tumour size, confirming the findings of van de Vijver et al., 1988. Another correlation was found between over-expression of c-erbB-2 tumours and histological grade. Berger et al., 1988; Barnes et al., 1988; Wright et al., 1989a; Gullick et al., 1991; Lovekin et al., 1991 came to the same results.
From this study we conclude that c-erbB-2 membranestaining tumours spread, especially to the liver, which confirms a previous prospective study with a short follow-up period (De Potter et al., 1989b) . The particular pattern of metastasis to the liver could be explained with the production of a factor in the liver which stimulates the growth and spread of c-erbB-2 tumour cells. This factor may also be present in foetal liver tissue where c-erbB-2 is expressed .
Our findings suggest that the putative ligand of c-erbB-2 is secreted into parenchymal organs in which the c-erbB-2 protein is expressed. The fact, that c-erbB-2 positive tumours show the tendency to select one parenchymal organ for metastising requires further investigation.
In conclusion our results show that c-erbB-2 positive tumours spread earlier. Most of the metastases are seen in the first three years after diagnosis. As a result of early metastases these patients have a shorter OST.
Our study is the first to provide us with an explanation for the discrepancies in literature between c-erbB-2 expression and different prognoses. Groups of authors who looked for a bad prognosis in the first years after diagnosis were able to show a difference in prognosis (Slamon et al., 1987; Varley et al., 1987; Gusterson et al., 1988; Thor et al., 1989; Tsuda et al., 1989; Wright et al., 1989a; De Potter et al., 1990) . Some authors who carried out investigations in a long follow-up period of more than 5 to 10 years did not find a difference in prognosis between c-erbB-2 positive and negative patients (Gusterson et al., 1988; van de Vivjer et al., 1988; Barnes et al., 1988) , other authors (Lovekin et al., 1991; Wistanley et al., 1991) found a difference in prognoses in a long follow-up period of more than 5 years between c-erbB-2 positive and negative patients. Our study only showed differences within a short follow-up period of up to 3 years in DFS and up to 4 years in OST and between c-erbB-2 positive and negative tumours. These differences vanish in a longer follow-up period up to 12 years.
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